<?xml version="1.0" encoding="UTF-8"?>
<ref id="B48-pharmaceuticals-13-00455">
 <label>48.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Del Re</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Citi</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Crucitta</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Rofi</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Belcari</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Van Schaik</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Danesi</surname>
    <given-names>R.</given-names>
   </name>
  </person-group>
  <article-title>Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?</article-title>
  <source>Pharmacol. Res.</source>
  <year>2016</year>
  <volume>107</volume>
  <fpage>398</fpage>
  <lpage>406</lpage>
  <pub-id pub-id-type="doi">10.1016/j.phrs.2016.03.025</pub-id>
  <pub-id pub-id-type="pmid">27060675</pub-id>
 </element-citation>
</ref>
